Radiomitigators: Breakthroughs in Post-Radiation Recovery.

Area of Science:

• Biomedical science
• Radiation oncology
• Pharmacology

Background:

• Ionizing radiation (IR) exposure presents significant health risks, necessitating effective medical countermeasures.
• Current countermeasures include radioprotectors, radiomitigators, and therapeutics, with radiomitigators offering post-exposure treatment advantages.

Purpose of the Study:

• To review the pathophysiological mechanisms of IR-induced injury.
• To summarize FDA-approved countermeasures and focus on promising radiomitigators.
• To discuss the translational potential of radiomitigators for emergency preparedness and oncology.

Main Methods:

• Literature review of pathophysiological mechanisms of IR injury.
• Analysis of preclinical and clinical data on radiomitigator efficacy.
• Examination of radiomitigator routes of administration and mechanisms of action.

Main Results:

• Radiomitigators show efficacy in preclinical models by modulating oxidative stress, enhancing DNA repair, preserving mitochondria, and regulating inflammation.
• Key mechanisms include preserving vascular integrity and promoting tissue repair.
• Clinical evidence supports the translational potential of these agents.

Conclusions:

• Radiomitigators are vital for managing radiation-induced injuries, offering a critical post-exposure therapeutic window.
• Optimizing radiomitigators requires addressing challenges in clinical translation and exploring combination therapies.
• Further research is needed to enhance survival and quality of life for individuals exposed to IR.